Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Andrea J. Bullock

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7143-0225; OpenAlex author ID A5071193838, A5076557106. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
143
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 26

  1. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Last author DOI 10.1080/14796694.2026.2664776↗
  2. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  3. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  4. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  5. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  6. A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer. Co-author DOI 10.7554/elife.87369↗
  7. A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer Co-author DOI 10.7554/elife.87369.3↗
  8. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  9. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-p… Co-author DOI 10.1007/s10637-021-01164-9↗
  10. Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX. Last author DOI 10.1136/bcr-2022-249370↗
  11. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4116↗
  12. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  13. Safety and efficacy of combination chemotherapy regimens in older adults with pancreatic ductal adenocarcinoma: a systematic review. Last author DOI 10.21037/jgo-21-87↗
  14. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-l… Co-author DOI 10.1007/s10637-019-00830-3↗
  15. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Last author DOI 10.1200/jco.20.00590↗
  16. Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy. Co-author DOI 10.18553/jmcp.2020.26.7.872↗
  17. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  18. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  19. Spontaneous regression of pancreatic cancer with liver metastases. Last author DOI 10.1136/bcr-2019-229619↗
  20. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  21. What Patients Look for When Browsing Online for Pancreatic Cancer: The Bait Behind the Byte. Co-author DOI 10.1007/s00268-018-4719-2↗
  22. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
  23. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  24. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo.2017.06.06↗
  25. Assessing the Accuracy and Readability of Online Health Information for Patients With Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2016.0730↗
  26. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. Co-author DOI 10.18632/oncotarget.8139↗

Closest collaborators

The 25 strongest of 143 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 9 shared papers, 2017–2026 · strength 0.95
  2. Kimmie Ng · 7 shared papers, 2017–2026 · strength 0.79
  3. Douglas Adam Rubinson · 6 shared papers, 2017–2026 · strength 0.63
  4. Jonathan Andrew Nowak · 6 shared papers, 2017–2026 · strength 0.63
  5. Bruno Bockorny · 4 shared papers, 2022–2025 · strength 0.60
  6. Andrew J. Aguirre · 5 shared papers, 2018–2026 · strength 0.58
  7. Leah H. Biller · 3 shared papers, 2021–2026 · strength 0.56
  8. Thomas E. Clancy · 6 shared papers, 2017–2024 · strength 0.51
  9. Mary Linton B. Peters · 3 shared papers, 2022–2026 · strength 0.45
  10. Ana Babić · 5 shared papers, 2017–2024 · strength 0.45
  11. Ling Huang · 3 shared papers, 2022–2024 · strength 0.45
  12. Joseph Elan Grossman · 3 shared papers, 2022–2024 · strength 0.45
  13. Leo L. Tsai · 3 shared papers, 2022–2024 · strength 0.45
  14. Senthil K. Muthuswamy · 3 shared papers, 2022–2024 · strength 0.45
  15. Mandeep Sawhney · 3 shared papers, 2022–2024 · strength 0.45
  16. Eileen Mary O'Reilly · 3 shared papers, 2019–2026 · strength 0.44
  17. Matthew B.B. Yurgelun · 3 shared papers, 2019–2026 · strength 0.40
  18. Kimberly J. Perez · 3 shared papers, 2019–2026 · strength 0.40
  19. Ehsan Irajizad · 3 shared papers, 2021–2024 · strength 0.35
  20. Michael D. Kluger · 3 shared papers, 2021–2024 · strength 0.35
  21. Johannes Francois Fahrmann · 3 shared papers, 2021–2024 · strength 0.35
  22. Samir Hanash · 3 shared papers, 2021–2024 · strength 0.35
  23. Anirban Maitra · 3 shared papers, 2021–2024 · strength 0.35
  24. Kunal Jajoo · 3 shared papers, 2021–2024 · strength 0.35
  25. John A. Chabot · 3 shared papers, 2021–2024 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.